Celgene Corporation (CELG): Today's Featured Drugs Winner

Celgene Corporation (CELG) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day up 0.7%. By the end of trading, Celgene Corporation rose $1.77 (2.5%) to $71.07 on average volume. Throughout the day, 3.1 million shares of Celgene Corporation exchanged hands as compared to its average daily volume of 3.7 million shares. The stock ranged in a price between $69.38-$71.39 after having opened the day at $69.66 as compared to the previous trading day's close of $69.30. Other companies within the Drugs industry that increased today were: Biosante Pharmaceuticals (BPAX), up 22.4%, iBio (IBIO), up 19.3%, OxiGene (OXGN), up 17.6%, and Chemocentryx (CCXI), up 15.6%.

• ACTIVE STOCK TRADERS: Check out TheStreet's special offer for Real Money, headlined by Jim Cramer, now!

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes various therapies to treat cancer and immune-inflammatory related diseases primarily in the United States and Europe. Celgene Corporation has a market cap of $29.43 billion and is part of the health care sector. The company has a P/E ratio of 19.9, equal to the average drugs industry P/E ratio and above the S&P 500 P/E ratio of 17.7. Shares are up 0.8% year to date as of the close of trading on Friday. Currently there are 25 analysts that rate Celgene Corporation a buy, no analysts rate it a sell, and two rate it a hold.

TheStreet Ratings rates Celgene Corporation as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, reasonable valuation levels and solid stock price performance. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook.

• You can view the full Celgene Ratings Report.

On the negative front, Exelixis (EXEL), down 13.1%, AVEO Pharmaceuticals (AVEO), down 10.3%, Senesco Technologies (SNT), down 9.7%, and Cytori Therapeutics (CYTX), down 7.9%, were all laggards within the drugs industry with Eli Lilly and Company (LLY) being today's drugs industry laggard.

• Use our drugs section to find industry-relevant news.
• Or find some new ideas from our top rated stocks lists.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF (XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech (BIS).

• Find other investment ideas from our top rated ETFs lists.

For more information on Celgene Corporation click any of the following:

• Celgene Corporation Stock Price

• Celgene Corporation Analyst Ratings

• Celgene Corporation Key Stats & Profile

• Celgene Corporation Earnings

• Celgene Corporation Ratio Comparison

• Celgene Corporation Growth Rates

• Celgene Corporation Balance Sheet

• Celgene Corporation Cash Flow

• Celgene Corporation Income Statement